DE60012183D1 - Verwendung einer makrolid-verbindung zur herstellung eines medikaments zur behandlung von gehirnschäden aufgrund von ischämie oder blutungen - Google Patents
Verwendung einer makrolid-verbindung zur herstellung eines medikaments zur behandlung von gehirnschäden aufgrund von ischämie oder blutungenInfo
- Publication number
- DE60012183D1 DE60012183D1 DE60012183T DE60012183T DE60012183D1 DE 60012183 D1 DE60012183 D1 DE 60012183D1 DE 60012183 T DE60012183 T DE 60012183T DE 60012183 T DE60012183 T DE 60012183T DE 60012183 D1 DE60012183 D1 DE 60012183D1
- Authority
- DE
- Germany
- Prior art keywords
- ischemia
- bleeding
- medicine
- producing
- damage due
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Saccharide Compounds (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9917158 | 1999-07-21 | ||
GBGB9917158.9A GB9917158D0 (en) | 1999-07-21 | 1999-07-21 | New use |
PCT/GB2000/002788 WO2001005385A2 (en) | 1999-07-21 | 2000-07-19 | New use of a macrolide compound for treating neurodegenerative disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60012183D1 true DE60012183D1 (de) | 2004-08-19 |
DE60012183T2 DE60012183T2 (de) | 2004-11-18 |
Family
ID=10857695
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE2000612183 Expired - Fee Related DE60012183T2 (de) | 1999-07-21 | 2000-07-19 | Verwendung einer makrolid-verbindung zur herstellung eines medikaments zur behandlung von gehirnschäden aufgrund von ischämie oder blutungen |
Country Status (15)
Country | Link |
---|---|
US (1) | US20060287353A1 (de) |
EP (1) | EP1196170B1 (de) |
JP (1) | JP2003504396A (de) |
KR (1) | KR100508623B1 (de) |
CN (1) | CN1200710C (de) |
AT (1) | ATE270888T1 (de) |
AU (1) | AU6003900A (de) |
CA (1) | CA2379140A1 (de) |
DE (1) | DE60012183T2 (de) |
DK (1) | DK1196170T3 (de) |
ES (1) | ES2220492T3 (de) |
GB (1) | GB9917158D0 (de) |
HK (1) | HK1047704B (de) |
PT (1) | PT1196170E (de) |
WO (1) | WO2001005385A2 (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR035411A1 (es) * | 2000-12-29 | 2004-05-26 | Fujisawa Pharmaceutical Co | Uso de un derivado de tacrolimus para fabricar un agente neurotrofico, composiciones y articulos de fabricacion o kits que lo comprenden, metodo para fabricar un agente que lo comprende y tejidos e injertos con una celula nerviosa tratada con este compuesto |
AU2003901023A0 (en) * | 2003-03-04 | 2003-03-20 | Fujisawa Pharmaceutical Co., Ltd. | New use |
KR20060125849A (ko) * | 2004-01-20 | 2006-12-06 | 아스텔라스세이야쿠 가부시키가이샤 | 발기부전 치료 방법 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4894366A (en) * | 1984-12-03 | 1990-01-16 | Fujisawa Pharmaceutical Company, Ltd. | Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same |
GB8728820D0 (en) * | 1987-12-09 | 1988-01-27 | Fisons Plc | Compounds |
GR1001225B (el) * | 1989-09-14 | 1993-06-30 | Fisons Plc | Νέαι μακροκυκλικαί ενώσεις και νέα μέ?οδος χρήσεως τους. |
GB9202196D0 (en) * | 1992-02-01 | 1992-03-18 | Fisons Plc | Method of treatment |
GB9218027D0 (en) * | 1992-08-25 | 1992-10-14 | Fisons Plc | Novel method of treatment |
GB9227055D0 (en) * | 1992-12-29 | 1993-02-24 | Fujisawa Pharmaceutical Co | New use |
-
1999
- 1999-07-21 GB GBGB9917158.9A patent/GB9917158D0/en not_active Ceased
-
2000
- 2000-07-19 AT AT00946165T patent/ATE270888T1/de not_active IP Right Cessation
- 2000-07-19 DK DK00946165T patent/DK1196170T3/da active
- 2000-07-19 CA CA002379140A patent/CA2379140A1/en not_active Abandoned
- 2000-07-19 ES ES00946165T patent/ES2220492T3/es not_active Expired - Lifetime
- 2000-07-19 AU AU60039/00A patent/AU6003900A/en not_active Abandoned
- 2000-07-19 CN CNB008105898A patent/CN1200710C/zh not_active Expired - Fee Related
- 2000-07-19 DE DE2000612183 patent/DE60012183T2/de not_active Expired - Fee Related
- 2000-07-19 PT PT00946165T patent/PT1196170E/pt unknown
- 2000-07-19 JP JP2001510442A patent/JP2003504396A/ja not_active Withdrawn
- 2000-07-19 EP EP00946165A patent/EP1196170B1/de not_active Expired - Lifetime
- 2000-07-19 KR KR10-2002-7000291A patent/KR100508623B1/ko not_active IP Right Cessation
- 2000-07-19 WO PCT/GB2000/002788 patent/WO2001005385A2/en active IP Right Grant
-
2002
- 2002-12-24 HK HK02109332.6A patent/HK1047704B/zh not_active IP Right Cessation
-
2006
- 2006-04-18 US US11/405,679 patent/US20060287353A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN1200710C (zh) | 2005-05-11 |
EP1196170B1 (de) | 2004-07-14 |
HK1047704B (zh) | 2005-12-16 |
ATE270888T1 (de) | 2004-07-15 |
EP1196170A2 (de) | 2002-04-17 |
US20060287353A1 (en) | 2006-12-21 |
CN1361691A (zh) | 2002-07-31 |
KR20020060148A (ko) | 2002-07-16 |
AU6003900A (en) | 2001-02-05 |
ES2220492T3 (es) | 2004-12-16 |
DK1196170T3 (da) | 2004-08-30 |
DE60012183T2 (de) | 2004-11-18 |
JP2003504396A (ja) | 2003-02-04 |
GB9917158D0 (en) | 1999-09-22 |
CA2379140A1 (en) | 2001-01-25 |
PT1196170E (pt) | 2004-10-29 |
HK1047704A1 (en) | 2003-03-07 |
WO2001005385A2 (en) | 2001-01-25 |
KR100508623B1 (ko) | 2005-08-17 |
WO2001005385A3 (en) | 2001-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0309964A (pt) | Derivados anticonvulsivos de sulfamoto substituìdo | |
CO2021015624A2 (es) | Compuestos de 1-oxo-isoindolin-5-carboxamida sustituída, composiciones de estos y métodos de tratamiento con dichos compuestos | |
NO20012896L (no) | Fremgangsmåte for behandling av cerebral ischemi og anvendelse av erytropoietin eller erytropoietinderivater forbehandling av cerebral ischemi | |
ES2176600T3 (es) | Derivado de la propiofenona y procedimientos para su preparacion. | |
BR0209821A (pt) | Compostos, processo para a manufatura desses compostos, composições farmacêuticas que compreendem os mesmos, processo para o tratamento e/ou profilaxia de enfermidades e utilização dos compostos | |
BR0010555A (pt) | Inibidores de neuraminidases | |
AR023388A1 (es) | INHIBIDORES DE aP2 DE BIFENILOS QUE CONTIENEN COMPUESTOS HETEROCICLICOS Y METODO DE TRATAMIENTO | |
DE60026152D1 (de) | Verwendung von stearidonsäure zur herstellung eines arzneimittels für die behandlung oder vorbeugung von krebs | |
AR007021A1 (es) | Derivados de 3-descladinosa-2,3-anhidroeritromicina, procedimientos para su preparacion, compuestos para su exclusivo uso en dichos procedimientosy procedimiento para su preparacion, una composicion farmaceutica para tratar infecciones bacterianas y el uso de estos compuestos para preparar medicamentos | |
WO2006078369A3 (en) | Methods and compositions for treatment of viral infections | |
DE69829202D1 (de) | Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen | |
BR0309753A (pt) | Processo para a preparação de derivados de 6-alquilideno penem | |
ATE246518T1 (de) | Egr-1 zur herstellung eines medikamentes zur behandlung von wunden | |
BRPI0410654A (pt) | composto, composição farmacêutica, uso de um composto, método para tratar um distúrbio de um paciente, e, processo para a preparação de um composto | |
DE60012183D1 (de) | Verwendung einer makrolid-verbindung zur herstellung eines medikaments zur behandlung von gehirnschäden aufgrund von ischämie oder blutungen | |
BR9911559A (pt) | Processo para a preparação de um composto, composto, processo para o tratamento de tumores resistentes a medicamento múltiplo, uso de um composto, e, agente e composição para tratar tumores resistentes a medicamento múltiplo. | |
BRPI0512951A (pt) | compostos, processo para sua fabricação, composições farmacêuticas contendo os mesmos, uso e método para tratamento e/ou prevenção de doenças que são moduladas pelos agonistas de ppar(delta) e/ou ppar(alpha) | |
ATE273006T1 (de) | Verwendung von polyzyklischen thiazol-systemen zur herstellung von medikamenten zur prophylaxe oder behandlung von obesitas | |
BRPI0414139A (pt) | métodos e composições para tratar infecções por herpes | |
ATE252383T1 (de) | Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen | |
ATE206052T1 (de) | Verwendung von sphingosin-1-phosphat, sphingosin- 1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten | |
BR0211121A (pt) | Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal | |
DE602004030661D1 (de) | Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis | |
DE60034110D1 (de) | Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien | |
ATE516038T1 (de) | Metallcluster-nanoverbindungen zur behandlung von tumorerkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8327 | Change in the person/name/address of the patent owner |
Owner name: ASTELLAS PHARMA INC., TOKIO/TOKYO, JP |
|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |